Literature DB >> 6388964

A rapid immunofluorescent procedure for serodiagnosis of Q fever in mice, guinea pigs, sheep, and humans.

M S Ascher, G S Horwith, M F Thornton, J R Greenwood, M A Berman.   

Abstract

The ability to diagnose Q fever has been hampered by the fact that diagnosis depends upon difficult serologic tests such as complement fixation (CF) or slide immunofluorescence performed only at reference laboratories. A new quantitative solid phase fluorescent antibody test (FIAX) has recently been developed and applied to measure antibodies in several microbial systems. The test takes less than 2 hr to perform and employs stable reagents. We have utilized this technique and developed a rapid immunofluorescent assay for detection of antibodies to Coxiella burnetii in man and animals. Sera from guinea pigs and mice immunized with phase I vaccine and from naturally infected sheep show high levels of fluorescence against both phase I and phase II antigens by this technique. We have tested over 100 CF positive humans from a recent laboratory outbreak of Q fever and find an excellent correlation between FIAX and CF results.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6388964

Source DB:  PubMed          Journal:  Diagn Immunol        ISSN: 0735-3111


  3 in total

1.  Enzyme immunoassay for Q fever: comparison with complement fixation and immunofluorescence tests and dot immunoblotting.

Authors:  R Cowley; F Fernandez; W Freemantle; D Rutter
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

2.  Serosurvey of Coxiella burnetii infection in dairy goat herds in Ontario. A comparison of two methods of enzyme-linked immunosorbent assay.

Authors:  G H Lang
Journal:  Can J Vet Res       Date:  1988-01       Impact factor: 1.310

3.  Humoral immune response to Q fever: enzyme-linked immunosorbent assay antibody response to Coxiella burnetii in experimentally infected guinea pigs.

Authors:  J C Williams; L A Thomas; M G Peacock
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.